Logo image of NXGL

NEXGEL INC (NXGL) Stock Fundamental Analysis

NASDAQ:NXGL - Nasdaq - US65344E1073 - Common Stock - Currency: USD

2.605  +0.02 (+0.58%)

Fundamental Rating

3

Taking everything into account, NXGL scores 3 out of 10 in our fundamental rating. NXGL was compared to 189 industry peers in the Health Care Equipment & Supplies industry. NXGL has a bad profitability rating. Also its financial health evaluation is rather negative. NXGL shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NXGL has reported negative net income.
In the past year NXGL has reported a negative cash flow from operations.
NXGL had negative earnings in each of the past 5 years.
NXGL had a negative operating cash flow in each of the past 5 years.
NXGL Yearly Net Income VS EBIT VS OCF VS FCFNXGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M

1.2 Ratios

The Return On Assets of NXGL (-29.87%) is comparable to the rest of the industry.
NXGL has a Return On Equity of -57.01%. This is comparable to the rest of the industry: NXGL outperforms 46.56% of its industry peers.
Industry RankSector Rank
ROA -29.87%
ROE -57.01%
ROIC N/A
ROA(3y)-35.81%
ROA(5y)-46.56%
ROE(3y)-62.13%
ROE(5y)-690.12%
ROIC(3y)N/A
ROIC(5y)N/A
NXGL Yearly ROA, ROE, ROICNXGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

NXGL has a worse Gross Margin (31.63%) than 74.60% of its industry peers.
NXGL's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for NXGL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 31.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y266%
GM growth 5YN/A
NXGL Yearly Profit, Operating, Gross MarginsNXGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

NXGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NXGL has more shares outstanding
The number of shares outstanding for NXGL has been increased compared to 5 years ago.
Compared to 1 year ago, NXGL has a worse debt to assets ratio.
NXGL Yearly Shares OutstandingNXGL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
NXGL Yearly Total Debt VS Total AssetsNXGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -0.01, we must say that NXGL is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NXGL (-0.01) is comparable to the rest of the industry.
NXGL has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
NXGL's Debt to Equity ratio of 0.16 is in line compared to the rest of the industry. NXGL outperforms 55.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z -0.01
ROIC/WACCN/A
WACC8.68%
NXGL Yearly LT Debt VS Equity VS FCFNXGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M 10M

2.3 Liquidity

A Current Ratio of 2.07 indicates that NXGL has no problem at all paying its short term obligations.
With a Current ratio value of 2.07, NXGL is not doing good in the industry: 65.08% of the companies in the same industry are doing better.
NXGL has a Quick Ratio of 1.36. This is a normal value and indicates that NXGL is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.36, NXGL is not doing good in the industry: 67.20% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.07
Quick Ratio 1.36
NXGL Yearly Current Assets VS Current LiabilitesNXGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.72% over the past year.
The Revenue has grown by 112.29% in the past year. This is a very strong growth!
Measured over the past years, NXGL shows a very strong growth in Revenue. The Revenue has been growing by 64.56% on average per year.
EPS 1Y (TTM)9.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.62%
Revenue 1Y (TTM)112.29%
Revenue growth 3Y77.64%
Revenue growth 5Y64.56%
Sales Q2Q%181.05%

3.2 Future

The Earnings Per Share is expected to grow by 49.41% on average over the next years. This is a very strong growth
Based on estimates for the next years, NXGL will show a very strong growth in Revenue. The Revenue will grow by 37.17% on average per year.
EPS Next Y87.76%
EPS Next 2Y72.01%
EPS Next 3Y61.64%
EPS Next 5Y49.41%
Revenue Next Year49.28%
Revenue Next 2Y42.56%
Revenue Next 3Y42.57%
Revenue Next 5Y37.17%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NXGL Yearly Revenue VS EstimatesNXGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M
NXGL Yearly EPS VS EstimatesNXGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NXGL. In the last year negative earnings were reported.
Also next year NXGL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NXGL Price Earnings VS Forward Price EarningsNXGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NXGL Per share dataNXGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

NXGL's earnings are expected to grow with 61.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y72.01%
EPS Next 3Y61.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NXGL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEXGEL INC

NASDAQ:NXGL (5/8/2025, 8:13:32 PM)

2.605

+0.02 (+0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-24 2025-03-24/amc
Earnings (Next)05-19 2025-05-19
Inst Owners6.05%
Inst Owner Change-0.13%
Ins Owners19.15%
Ins Owner Change-0.01%
Market Cap19.93M
Analysts82.86
Price Target6.12 (134.93%)
Short Float %1.59%
Short Ratio2.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.84%
Min EPS beat(2)-7.84%
Max EPS beat(2)-7.84%
EPS beat(4)2
Avg EPS beat(4)2.51%
Min EPS beat(4)-7.84%
Max EPS beat(4)23.75%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.44%
Min Revenue beat(2)-0.36%
Max Revenue beat(2)1.24%
Revenue beat(4)3
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-0.36%
Max Revenue beat(4)2.84%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-300%
EPS NY rev (3m)-300%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.29
P/FCF N/A
P/OCF N/A
P/B 3.46
P/tB 5.22
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS1.14
BVpS0.75
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.87%
ROE -57.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 31.63%
FCFM N/A
ROA(3y)-35.81%
ROA(5y)-46.56%
ROE(3y)-62.13%
ROE(5y)-690.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y266%
GM growth 5YN/A
F-Score4
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 101.61%
Cap/Sales 5.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.07
Quick Ratio 1.36
Altman-Z -0.01
F-Score4
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)166.83%
Cap/Depr(5y)273.19%
Cap/Sales(3y)9%
Cap/Sales(5y)18.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.62%
EPS Next Y87.76%
EPS Next 2Y72.01%
EPS Next 3Y61.64%
EPS Next 5Y49.41%
Revenue 1Y (TTM)112.29%
Revenue growth 3Y77.64%
Revenue growth 5Y64.56%
Sales Q2Q%181.05%
Revenue Next Year49.28%
Revenue Next 2Y42.56%
Revenue Next 3Y42.57%
Revenue Next 5Y37.17%
EBIT growth 1Y-2.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.5%
OCF growth 3YN/A
OCF growth 5YN/A